Published in Virus Res on August 16, 2011
Circumventing antivector immunity: potential use of nonhuman adenoviral vectors. Hum Gene Ther (2014) 0.79
Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J Gen Virol (1977) 41.93
Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy. Proc Natl Acad Sci U S A (1994) 8.13
Frequency and stability of chromosomal integration of adenovirus vectors. J Virol (1999) 2.18
Update on adenovirus and its vectors. J Gen Virol (2000) 1.93
Cellular immune response to adenoviral vector infected cells does not require de novo viral gene expression: implications for gene therapy. Proc Natl Acad Sci U S A (1998) 1.76
Current strategies and future directions for eluding adenoviral vector immunity. Curr Gene Ther (2006) 1.42
Tumor necrosis factor alpha plays a central role in immune-mediated clearance of adenoviral vectors. Proc Natl Acad Sci U S A (1997) 1.37
Circumvention of vector-specific neutralizing antibody response by alternating use of human and non-human adenoviruses: implications in gene therapy. Virology (2000) 1.30
Development of nonhuman adenoviruses as vaccine vectors. Vaccine (2005) 1.25
Comparative transduction efficiencies of human and nonhuman adenoviral vectors in human, murine, bovine, and porcine cells in culture. Biochem Biophys Res Commun (2005) 1.19
New serotypes of adenoviral vectors. Curr Opin Mol Ther (2006) 1.08
Episomal persistence of recombinant adenoviral vector genomes during the cell cycle in vivo. J Virol (2003) 1.06
Porcine adenoviral vectors evade preexisting humoral immunity to adenoviruses and efficiently infect both human and murine cells in culture. Virus Res (2004) 1.03
High-efficiency stable gene transfer of adenovirus into mammalian cells using ionizing radiation. Hum Gene Ther (1997) 1.02
Adenoviral vector-based strategies for cancer therapy. Curr Drug ther (2009) 1.02
Characterization of bovine adenovirus type 3 E1 proteins and isolation of E1-expressing cell lines. Virology (2002) 1.02
An adenovirus vector with a chimeric fiber derived from canine adenovirus type 2 displays novel tropism. Virology (2004) 1.02
Comparative analysis of vector biodistribution, persistence and gene expression following intravenous delivery of bovine, porcine and human adenoviral vectors in a mouse model. Virology (2009) 1.02
Production of adenovirus vectors and their use as a delivery system for influenza vaccines. Expert Opin Biol Ther (2010) 1.01
Long-term transgene expression in proliferating cells mediated by episomally maintained high-capacity adenovirus vectors. J Virol (2004) 0.99
Development of a bovine adenovirus type 3-based expression vector. J Gen Virol (1995) 0.99
The role of selectins and integrins in adenovirus vector-induced neutrophil recruitment to the liver. Eur J Immunol (2002) 0.97
Bovine adenovirus type 3 internalization is independent of primary receptors of human adenovirus type 5 and porcine adenovirus type 3. Biochem Biophys Res Commun (2005) 0.91
Episomal vectors for gene therapy. Curr Gene Ther (2008) 0.91
Porcine adenovirus serotype 3 internalization is independent of CAR and alphavbeta3 or alphavbeta5 integrin. Virology (2005) 0.90
Evaluation of cross-reactive cell-mediated immune responses among human, bovine and porcine adenoviruses. Gene Ther (2010) 0.90
Multiple copies of human adenovirus 12 genomes are integrated in virus-induced hamster tumors. J Virol (1977) 0.90
Porcine adenovirus-3 as a helper-dependent expression vector. J Gen Virol (1999) 0.90
The structure of adenovirus type 12 DNA integration sites in the hamster cell genome. J Virol (1996) 0.89
Development of adenoviral-vector-based pandemic influenza vaccine against antigenically distinct human H5N1 strains in mice. Lancet (2006) 2.10
Bovine adenoviral vector-based H5N1 influenza vaccine overcomes exceptionally high levels of pre-existing immunity against human adenovirus. Mol Ther (2008) 1.84
Emerging strategies for EphA2 receptor targeting for cancer therapeutics. Expert Opin Ther Targets (2011) 1.65
Decreased tumorigenic potential of EphA2-overexpressing breast cancer cells following treatment with adenoviral vectors that express EphrinA1. Cancer Gene Ther (2004) 1.49
Current strategies and future directions for eluding adenoviral vector immunity. Curr Gene Ther (2006) 1.42
Development of nonhuman adenoviruses as vaccine vectors. Vaccine (2005) 1.25
Expression of EphA2 and Ephrin A-1 in carcinoma of the urinary bladder. Clin Cancer Res (2006) 1.24
Comparative transduction efficiencies of human and nonhuman adenoviral vectors in human, murine, bovine, and porcine cells in culture. Biochem Biophys Res Commun (2005) 1.19
A broadly protective vaccine against globally dispersed clade 1 and clade 2 H5N1 influenza viruses. J Infect Dis (2008) 1.13
Adenoviral vector immunity: its implications and circumvention strategies. Curr Gene Ther (2011) 1.07
Porcine adenoviral vectors evade preexisting humoral immunity to adenoviruses and efficiently infect both human and murine cells in culture. Virus Res (2004) 1.03
Characterization of bovine adenovirus type 3 E1 proteins and isolation of E1-expressing cell lines. Virology (2002) 1.02
Porcine circovirus type 2 (PCV2) causes apoptosis in experimentally inoculated BALB/c mice. BMC Vet Res (2005) 1.02
Adenoviral vector-based strategies for cancer therapy. Curr Drug ther (2009) 1.02
Comparative analysis of vector biodistribution, persistence and gene expression following intravenous delivery of bovine, porcine and human adenoviral vectors in a mouse model. Virology (2009) 1.02
Production of adenovirus vectors and their use as a delivery system for influenza vaccines. Expert Opin Biol Ther (2010) 1.01
Impact of preexisting adenovirus vector immunity on immunogenicity and protection conferred with an adenovirus-based H5N1 influenza vaccine. PLoS One (2012) 1.00
Adenovirus receptors and their implications in gene delivery. Virus Res (2009) 0.98
Immunocompetent mouse model of breast cancer for preclinical testing of EphA2-targeted therapy. Cancer Gene Ther (2005) 0.95
Avian influenza pandemic preparedness: developing prepandemic and pandemic vaccines against a moving target. Expert Rev Mol Med (2010) 0.93
Broadly protective adenovirus-based multivalent vaccines against highly pathogenic avian influenza viruses for pandemic preparedness. PLoS One (2013) 0.93
Evaluation of innate immunity and vector toxicity following inoculation of bovine, porcine or human adenoviral vectors in a mouse model. Virus Res (2010) 0.93
Bovine adenovirus type 3 internalization is independent of primary receptors of human adenovirus type 5 and porcine adenovirus type 3. Biochem Biophys Res Commun (2005) 0.91
Porcine adenovirus serotype 3 internalization is independent of CAR and alphavbeta3 or alphavbeta5 integrin. Virology (2005) 0.90
Bovine adenovirus serotype 3 utilizes sialic acid as a cellular receptor for virus entry. Virology (2009) 0.88
Modulation of PKR activity in cells infected by bovine viral diarrhea virus. Virus Res (2005) 0.86
Egg-independent vaccine strategies for highly pathogenic H5N1 influenza viruses. Hum Vaccin (2010) 0.85
Sequence analysis of old and new strains of porcine circovirus associated with congenital tremors in pigs and their comparison with strains involved with postweaning multisystemic wasting syndrome. Can J Vet Res (2002) 0.83
EphrinA1-EphA2 interaction-mediated apoptosis and FMS-like tyrosine kinase 3 receptor ligand-induced immunotherapy inhibit tumor growth in a breast cancer mouse model. J Gene Med (2012) 0.80
Adenoviral E2 IVa2 protein interacts with L4 33K protein and E2 DNA-binding protein. J Gen Virol (2013) 0.79
Sequential administration of bovine and human adenovirus vectors to overcome vector immunity in an immunocompetent mouse model of breast cancer. Virus Res (2011) 0.78
Adenoviral vector expressing murine β-defensin 2 enhances immunogenicity of an adenoviral vector based H5N1 influenza vaccine in aged mice. Virus Res (2013) 0.77
A 72-bp internal deletion in the left inverted terminal repeat of the bovine adenovirus type 3 genome does not affect virus replication. Intervirology (2002) 0.77
Beta-defensin 2 enhances immunogenicity and protection of an adenovirus-based H5N1 influenza vaccine at an early time. Virus Res (2013) 0.75
Corrigendum: KANK1 inhibits cell growth by inducing apoptosis through regulating CXXC5 in human malignant peripheral nerve sheath tumors. Sci Rep (2017) 0.75